Health News

Case Report Suggests Microbiome Therapeutics' NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control

Author: Australian Business

BROOMFIELD, Colo., Sept. 11, 2013 /PRNewswire/ -- MicroBiome Therapeutics LLC, (MBT), a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report......

More...

More Articles...

Polyether Ether Ketone (PEEK) Market worth $831 Million by 2018
Accel-KKR Makes a Majority Investment in EA Holdings, Inc. to Accelerate Company's Growth
WebMD Health Corp. Announces Preliminary Results of Its Tender Offer
SAIC Outlines Business Objectives For Leidos, A National Security, Health Engineering Solutions Leader
Elsevier and Energy Institute Organize First Energy Systems Conference To Be Held in June 2014, London, UK
Quantum Materials Establishes Milestone as First Company to Deliver Tetrapod Quantum Dot Samples to LCD Display Manufacturer
University of Florida Clinical and Translational Research Building Augments Perkins+Will's Portfolio of Future-Defining Science and Technology Projects
Parenteral Drug Association Elections Begin
invendo medical Appoints Chief Operating And Chief Technology Officer
BIO-tract® probiotisches Verabreichungssystem jetzt in 33 Ländern patentiert

Page 1824 of 1906